Pila Pharma (PILA) H1 2026 earnings summary

Executive summary

• Regulatory approval received for a 12-week clinical trial (PP-CT04) of XEN-D0501 in obesity, marking a significant step in clinical development.

• Focus remains on advancing TRPV1 antagonist for obesity, diabetes, and rare disease erythromelalgia.

• The company operates virtually, relying on consultants and CROs for R&D activities.

Financial highlights

• Operating income was TSEK 0, down from TSEK 851 in the same period last year.

• EBIT for the first half was TSEK -3,850, an improvement from TSEK -4,092 year-over-year.

• Net result for the period was TSEK -3,867, compared to TSEK -4,102 year-over-year.

• Cash flow from operating activities was TSEK -17,974, including a TSEK 13,195 transfer to the Danish subsidiary.

• Cash at period end: TSEK 3,257 (parent) and TSEK 10,126 (Danish subsidiary).

Outlook and guidance

• The new clinical trial aims to establish safety and efficacy at higher doses and longer durations, potentially enabling further studies in obesity and related diseases.

• No explicit financial or revenue guidance provided for the remainder of the year.